NCT00311090 - Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs | Biotech Hunter

Enrollment

757

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Deep Venous Thrombosis

Interventions

DRUG

Idrabiotaparinux sodium

"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"

DRUG

Idraparinux sodium

"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"

DRUG

Avidin

"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"

DRUG

Placebo (for Avidin)

"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"

Trial Locations (20)

1220

Sanofi-Aventis, Vienna

1642

Sanofi-Aventis, Buenos Aires

1685

Sanofi-Aventis, Midrand

1831

Sanofi-Aventis, Diegem

103045

Sanofi-aventis, Moscow

08807

Sanofi-Aventis, Bridgewater

NSW 2113

Sanofi-Aventis, Macquarie Park

05677-000

Sanofi-Aventis, São Paulo

H7L 4A8

Sanofi-Aventis, Laval

160 00

Sanofi-Aventis, Prague

Unknown

Sanofi-Aventis, Copenhagen

sanofi-aventis France, Paris

sanofi-aventis Israel, Netanya

Sanofi-aventis, Milan

sanofi-aventis Mexico, México

sanofi-aventis, Netherlands, Gouda

Sanofi-Aventis, New Zealand

sanofi-aventis Turkey, Istanbul

02-672

Sanofi-Aventis, Warsaw

08019

Sanofi-Aventis, Barcelona